Daiichi Sankyo Company, Limited

Ranbaxy Laboratories, Inc.

Punit Kumar Srivastava

Sunanda Ghosh Dastidar

Venkata Poornapragnacharyulu Palle

Rie Miyauchi

Shin Iimura

Masatoshi Nagamochi

Ashwani Kumar Verma

Masayuki Ishizaki

Manoj Kumar Khera

Viswajanani Jitendra Sattigeri

Ranadheer Reddy

Manoj Kumar Tiwari

Ajay Soni

Abdul Rehman Abdul Rauf

Sony Joseph

Arpita Musib

Kumaragurubaran Nagaswamy

Lalima Sharma

Rijwan Jaffer Momin

Pradip Balu Wagh

Soma Ghosh

Sonali Nanasaheb Pansare

Pramod Raosaheb Markad

Balkrishna Ramchandra Kale

Yogesh Balasaheb Khairnar

Aniruddha Mondal

Takeshi Murata

Viswajanani J Sattigeri

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R, Rand Rare as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

Heterocyclic compounds as protein kinase inhibitors

The present invention relates to &#x3b2;-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure &#x3b2;-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.

Matrix metalloproteinase inhibitors

The present invention relates to &#x3b2;-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure &#x3b2;-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

Growing community of inventors

Gurgaon, India

Punit Kumar Srivastava